Sittner & Nelson’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.07M Buy
1,166
+20
+2% +$20.3K 0.39% 59
2025
Q4
$1.21M Buy
1,146
+93
+9% +$88.9K 0.43% 53
2025
Q3
$803K Hold
1,053
0.29% 61
2025
Q2
$821K Hold
1,053
0.33% 56
2025
Q1
$870K Buy
1,053
+45
+4% +$37.4K 0.37% 49
2024
Q4
$778K Buy
1,008
+2
+0.2% +$1.66K 0.34% 52
2024
Q3
$891K Hold
1,006
0.4% 46
2024
Q2
$911K Buy
1,006
+3
+0.3% +$2.4K 0.45% 45
2024
Q1
$780K Hold
1,003
0.39% 49
2023
Q4
$585K Hold
1,003
0.31% 55
2023
Q3
$539K Sell
1,003
-25
-2% -$12.9K 0.31% 58
2023
Q2
$482K Buy
1,028
+25
+2% +$10.5K 0.26% 62
2023
Q1
$344K Buy
1,003
+26
+3% +$8.77K 0.2% 85
2022
Q4
$357K Buy
977
+1
+0.1% +$355 0.22% 83
2022
Q3
$316K Buy
976
+460
+89% +$146K 0.21% 83
2022
Q2
$167K Hold
516
0.11% 114
2022
Q1
$148K Sell
516
-9
-2% -$2.32K 0.09% 120
2021
Q4
$145K Hold
525
0.08% 121
2021
Q3
$121K Hold
525
0.08% 127
2021
Q2
$120K Hold
525
0.08% 118
2021
Q1
$98K Sell
525
-19
-3% -$3.72K 0.07% 125
2020
Q4
$92K Buy
+544
New +$81.2K 0.08% 119

Other funds holding LLY

Sittner & Nelson's LLY Position: Q1 2026 in Review

Sittner & Nelson increased its Eli Lilly (LLY) stake by 1.7% in Q1 2026, buying an estimated $20.3K and bringing the position to 1,166 shares worth $1.07M. The position accounts for 0.39% of the portfolio, ranked #59.

Sittner & Nelson first reported a position in LLY in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.21M in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Sittner & Nelson held 1,166 shares of Eli Lilly worth $1.07M as of Q1 2026.
  • Sittner & Nelson bought 20 Eli Lilly shares in Q1 2026, an estimated $20.3K.
  • Eli Lilly made up 0.39% of Sittner & Nelson's portfolio in Q1 2026, its #59 holding.
  • Sittner & Nelson first reported a position in Eli Lilly in Q4 2020 and has held it in 22 quarters since.
  • Sittner & Nelson's Eli Lilly position peaked at $1.21M in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Sittner & Nelson's 13F filing for Q1 2026, filed 12 May 2026.